米可纳通过抑制结肠衰老,NF-κB信号和肠道微生物群调节来缓解结肠炎
Fuxing Li1, Shujia Song1, Mingming Huang2
1School of Basic Medicine, Dali University, Dali, Yunnan 671000, China.
抗真菌药物米可纳 (MCZ) 在性结肠炎 (UC) 模型中减少结肠炎和细胞衰老. 它通过改变肠道细菌和阻断NF-κB炎症途径来起作用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,与肠道上皮细胞衰老和炎症有关.
- 抗真菌药物miconazole (MCZ) 显示出UC治疗的潜力,但其机制尚未完全理解.
研究的目的:
- 调查麦可纳 (MCZ) 在性结肠炎 (UC) 中的抗衰老和抗炎作用.
- 阐明UC中MCZ作用的潜在机制,包括其对细胞衰老,微生物群和炎症通路的影响.
主要方法:
- 化合物库查确定了MCZ在结肠NCM460细胞中抑制硫酸 (DSS) 诱导衰老的能力.
- 在DSS诱导的UC动物模型中评估了MCZ的影响,评估了体重减轻,便状况和结肠组织损伤.
- 机理学研究涉及分析衰老标志物 (SA-β-Gal,P16/P21),肠道微生物群组成和NF-κB信号通路激活.
主要成果:
- 在DSS治疗的细胞中,MCZ显著降低了衰老细胞和P16/P21表达的比例.
- 在体内,MCZ治疗改善了DSS诱导的UC症状和结肠损伤.
- MCZ调节了肠道微生物群,促进有益的细菌和抑制有害的细菌,同时也抑制了NF-κB通路的酸化.
结论:
- 米可纳 (MCZ) 显示出与性结肠炎 (UC) 治疗相关的新型抗衰老和抗炎性质.
- MCZ的治疗效果是通过微生物群调节和抑制NF-κB信号通路的介导.
- 这些发现表明MCZ是UC的潜在治疗剂,提供新的治疗策略.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
06:24Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Constipation-Predominant IBS
